GMAB

Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period

12/12 02:35 am

Genmab to Hold 2025 R&D Update and ASH Data Review Meeting

12/11 03:00 am

Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)

12/08 05:30 pm

Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma

12/07 08:50 am

Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)

12/06 10:30 am

Genmab Announces Closing of Private Offering of Senior Secured Notes and Senior Unsecured Notes

12/03 04:03 pm

Capital Increase in Genmab as a Result of Employee Warrant Exercise

11/18 03:58 pm

Genmab to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference in London

11/05 01:58 pm

CD40 Targeting Therapy Clinical Trials Anti CD40 Antibody Therapy Market Opportunity Assessment Insight

10/14 01:52 pm

Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough

09/29 10:15 am

Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket

09/29 05:07 am

Grant of Restricted Stock Units and Warrants to Employees in Genmab

09/25 07:14 pm

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

09/24 02:30 am

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

09/09 02:57 pm

Capital Increase in Genmab as a Result of Employee Warrant Exercise

09/09 02:54 pm

SpyGlass Pharma Appoints Elizabeth O’Farrell to its Board of Directors

08/19 08:00 am

Capital Increase in Genmab as a Result of Employee Warrant Exercise

08/12 02:36 pm

Genmab Announces Epcoritamab Investigational Combination Therapy Demonstrates High Response Rates in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Eligible for Autologous Stem Cell Transplantation (ASCT)

06/15 05:00 am

Genmab Announces Investigational Rinatabart Sesutecan (Rina-S®) Demonstrates Encouraging Anti-Tumor Activity in Heavily Pretreated Patients with Advanced Endometrial Cancer in Phase 1/2 RAINFOL™-01 Trial

06/02 02:30 pm

Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

05/01 08:14 pm

Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts

04/11 10:50 am

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

03/21 11:29 pm

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

02/28 05:00 pm

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

01/03 02:56 pm

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

12/09 01:00 pm

CD40 Targeted Therapies Clinical Trials & Market Opportunity Report 2025, Insight By Company, Country, Indication & Phase

12/09 05:48 am

Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)

12/07 08:12 pm

Grant of Restricted Stock Units and Warrants to Employees in Genmab

11/21 03:48 pm

Genmab to Present at Jefferies London Healthcare Conference

11/05 02:11 pm

Down -14.68% in 4 Weeks, Here's Why Genmab Looks Ripe for a Turnaround

10/08 02:06 pm

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial

09/15 08:45 am

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

08/26 12:26 pm

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

08/13 02:53 pm

Capital Increase in Genmab as a Result of Employee Warrant Exercise

08/13 02:51 pm

Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?

08/01 11:41 am

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024 - GlobeNewswire

07/17 06:26 am

ISS suggest Enhabit shareholders elect three AREX Capital nominees to board By Reuters - Investing.com

07/12 11:42 am

Antibody Drug Conjugates Market Insights 2018-2023 and - GlobeNewswire

07/12 06:40 am

AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock? - Zacks Investment Research

07/11 09:32 am

AbbVie (ABBV) Gets CHMP Nod for Lymphoma Drug's Expanded Use

07/01 08:37 am

AbbVie/Genmab's Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway

06/27 01:22 pm

FDA Expands AbbVie's (ABBV) Epkinly Label in Follicular Lymphoma

06/27 11:03 am

What 9 Analyst Ratings Have To Say About Genmab

05/20 11:00 am

Decoding 9 Analyst Evaluations For Genmab

04/30 08:00 am

AbbVie (ABBV) Beats on Q1 Earnings & Sales, Ups '24 EPS View

04/26 12:10 pm

Analyst Ratings For Genmab

03/26 10:00 am

4 Analysts Assess Genmab: What You Need To Know

02/20 11:00 am

Cracking The Code: Understanding Analyst Reviews For Genmab

01/29 08:00 am

What's Going On With Danish Healthcare Firm Genmab Stock?

01/23 02:11 pm

New Strong Buy Stocks for January 17th

01/17 08:06 am